transmission, and the decision was made to discontinue the HIS was prepared by pooling sera from 2 juvenile and 4 adult ACTG 185 trial [19] .
rhesus macaques that had previously been immunized with live It is still important to know, however, whether increased attenuated SIV mac 1A11 [28] ; several of these animals had received levels of anti -HIV antibodies can reduce vertical transmission, a booster immunization with either live attenuated SIV mac 1A11 or especially for developing countries, where prolonged chemowhole inactivated SIV (which was prepared according to methods prophylactic treatment with antiviral drugs is not feasible. An described previously [2] ). After immunization, each of the 6 appropriate animal model can be very useful for studying the animals was challenged intravenously or intravaginally with potential of passive immunization strategies for preventing SIV mac 251 propagated in rhesus PBMC and maintained low virus transmission or disease. levels over 2 months to 4 years after challenge (unpublished data).
Simian immunodeficiency virus (SIV) infection of rhesus
These 6 macaques had no detectable plasma viremia, high anti-SIV antibody titers (by ELISA), and no clinical illness at the macaques is an excellent animal model of HIV infection in time serum was collected. Normal control serum was prepared by humans [20, 21] . We have previously demonstrated that SIV mac pooling serum from 5 healthy SIV-seronegative adult macaques.
infection of newborn macaques is a useful animal model of All sera were heat-inactivated for 1 h at 56ЊC before pooling.
human pediatric HIV infection that allows rapid evaluation of Pooled sera were then aliquoted and stored at 070ЊC until use.
intervention strategies [22 -26] . We have also demonstrated
The absence of infectious SIV in the serum was confirmed by that vaccination of pregnant macaques against SIV resulted in culturing a serum aliquot with CEMx174 cells and monitoring p27 transplacental antibody transfer that protected 2 of 3 newborn core antigen according to methods previously described [29] . Total macaques against oral-conjunctival SIV infection at birth [2] .
protein levels in the pooled sera were determined by the Coulter To further explore the role of passively acquired antiviral DART Total Protein Assay (a modified biuret method) run on the antibodies, the present study focused on determining whether DACOS chemistry analyzer (Coulter, Hialeah, FL). Total IgG levpassive immunization of newborn macaques with SIV hyperimels were determined by two techniques: a human IgG radial immunodiffusion kit (The Binding Site, Birmingham, UK) and a rhesus mune serum (SIV-HIS) before or after oral SIV exposure could monkey-specific IgG radial immunodiffusion assay [30] . Levels prevent infection or modulate the disease course.
of RANTES chemokine in sera were determined (Quantikine Human RANTES Immunoassay; R&D Systems, Minneapolis).
Virus neutralization assay. Neutralization assays were per-
Materials and Methods
formed with CEMx174 cells using heat-inactivated (56ЊC, 1 h) plasma from preservative-free heparinized blood. Neutralization Animals and sampling. Sixteen newborn rhesus macaques was measured by a reduction in virus-induced cell killing as de-(Macaca mulatta) from simian type D retrovirus-free and SIVscribed previously [31] . Briefly, cell-free virus (50 mL containing seronegative dams at the California Regional Primate Research 0.5-1 ng of p27) was added to multiple dilutions of test plasmas Center were removed from their mothers and reared in a primate in 100 mL of growth medium in triplicate wells of 96-well microtinursery. When necessary, animals were immobilized with [10] [11] [12] [13] [14] [15] ter plates. Virus-plasma mixtures were incubated at 37ЊC for 1 h, mg/kg ketamine HCL (Parke-Davis, Morris Plains, NJ) injected and then CEMx174 cells (10 5 cells in 100 mL) were added to each intramuscularly. Samples were collected immediately before virus well. Cell densities were reduced, and the medium was replaced inoculation or serum administration and regularly thereafter for after 3 days of incubation. Infection led to extensive syncytium monitoring viral and immunologic parameters; 0.5-1 mL of blood formation and virus-induced cell killing in Ç6 days in the absence (heparinized) was taken weekly for the first month, every 2 weeks of antibodies. Neutralization was measured by staining viable cells for the next 6 months, and then monthly. Complete blood cell with Finter's neutral red in poly-L-lysine-coated plates. Percent counts were done with EDTA-anticoagulated blood samples from protection was determined by calculating the difference in absorpall animals. Samples were analyzed by using an automated election (A 540 ) between test wells (cells / plasma sample / virus) and tronic cell counter (Baker 9000; Serono Baker Diagnostics, Bethlevirus control wells (cells / virus) and dividing this result by the hem, PA); differential blood cell counts were done manually.
difference in absorption between cell control wells (cells only) Saliva samples were taken with Omni-Sal collectors (Saliva Diagand virus control wells. Neutralization was measured when virusnostic Systems, Vancouver, WA).
induced cell-killing in virus control wells was ú70% but õ100%. Virus inoculation of newborn macaques. Within 3 days of age, Neutralizing titers are given as the reciprocal of the plasma dilution newborn macaques were inoculated orally with 1 mL of an unrequired to protect 50% of cells from virus-induced killing. cloned SIV mac 251 virus stock, administered atraumatically by disVirus stocks were grown in H9 cells or stimulated rhesus PBMC pensing the inoculum slowly into the mouth; animals were monias described [31] . Virus-containing culture supernatants were made tored to ensure that the inoculum was swallowed. The virus stock cell-free by low-speed centrifugation and filtration (0.45 mm) and used in this study consisted of uncloned SIV mac 251 propagated on stored in aliquots at 070ЊC. The concentration of virus was deterrhesus peripheral blood mononuclear cells (PBMC) with a titer of mined by p27 gag immunoassay as described by the supplier 10 5 TCID 50 /mL [27] . This SIV mac 251 stock has been shown to (Coulter). . Measurements of end-point titer, conformational dependence, and antibody avidity were determined as previously avidity, and those with index values ú50% were designated high avidity [36] . described [34] .
In brief, for the measurement of end-point titer, preparations of While measurements of antibody conformational dependence and antibody avidity were performed at dilutions producing an density gradient-purified SIV/B7 were used as a source of viral envelope glycoproteins [35] . Immulon II 96-well plates (Dynatech, OD at 450 nm of 1.0-1.5 in the end-point titer ConA ELISA, experiments using several different dilutions within this linear Chantilly, VA) coated with 2.5 mg/well ConA (Vector Laboratories, Burlingame, CA) were used to adsorb the native envelope range were performed to ensure that the variation in actual values was within 10%. glycoproteins from Triton X-100-disrupted SIV/B7. The ConAadsorbed glycoprotein wells were then incubated with heat-inactiQuantitative virus isolation. Cell-associated and cell-free virus levels in peripheral blood were determined regularly by limiting diluvated SIV-HIS to capture envelope-specific serum antibodies, extensively washed with PBS, and incubated with a peroxidase-contion culture (four replicates per dilution) of PBMC and plasma, respectively, with CEMx174 cells in 24-well plates and subsequent p27 jugated anti-monkey IgG (Sigma, St. Louis). Wells were again washed with PBS and incubated with TM Blue substrate (Intergen, core antigen measurement, according to methods previously described [2, 29, 37, 38]. Virus levels were calculated according to the method Milford, MA) before color development was determined after the reaction was stopped by the addition of 1 N sulfuric acid. Antibody of Reed and Muench [39] and expressed as TCID 50 /10 6 PBMC or per milliliter of plasma [38] . In addition, for animals with low or reactivity to the ConA-anchored glycoprotein was determined by measuring the optical density (OD) at 450 nm using an automated undetectable virus load, 1 1 10 6 to 5 1 10 6 PBMC were cocultivated for 8 weeks with CEMx174 cells in tissue culture flasks, as described plate reader (Titertek; Flow Laboratories, Inglewood, CA). Endpoint titers were defined as the last 2-fold dilution with an OD previously [37, 38] . Polymerase chain reaction (PCR) amplification. Nested PCR twice that of normal monkey serum at the lowest dilution (1:50) or 0.100, whichever value was greater.
was carried out in a GeneAmp 9600 (Perkin-Elmer Cetus, Emeryville, CA). Two rounds of 30 cycles of amplification were Serum samples were analyzed for conformational dependence by comparing the serum antibody reactivities to native and denaperformed on aliquots of plasmid DNA containing the complete genome of SIV mac 1A11 [28] (positive control) or aliquots of PBMC tured viral envelope glycoprotein substrates in the ConA ELISA as previously described [34] . Briefly, native (Triton X-100-disrupted lysates using SIV mac -specific gag primers and conditions described elsewhere [37, 40] . This nested PCR amplification procedure SIV/B7) or denatured (reduced and carboxyamidated SIV/B7) envelope substrates were captured onto 96-well microtiter plates usallows visual detection of a single copy of SIV gag sequences in as many as 200,000 PBMC [40] . ing ConA. Sera (diluted to produce an OD at 450 nm of 1.0-1.5 in the end-point titer ConA ELISA procedure) were reacted in Anti-SIV isotype-specific antibody determination in plasma and saliva. The anti-SIV isotype-specific antibody ELISAs triplicate wells with either native or denatured glycoprotein substrates, washed extensively with PBS, incubated with peroxidasehave been described [2, 23, 25] . The SIV-specific IgG and IgA antibody ELISA uses microtiter ELISA plates (Falcon 3912; Becconjugated anti-monkey IgG and then with TM Blue substrate, and developed as described above for the end-point titer ConA ton Dickinson, San Jose, CA) coated with whole SIV mac 251 (Advanced Biotechnologies, Columbia, MD) at 500 ng of total protein ELISA. A conformation ratio was then calculated from the ratio of antibody reactivities to native versus denatured envelope glycoper well. These plates were incubated with test or control plasma (4-fold dilutions starting at 1:100) or saliva (2-fold dilutions startprotein substrates. Thus, the conformation ratio is a direct measure of the conformational dependence of the binding of a particular ing at 1:4) samples, washed, then incubated with 1:2000 diluted enzyme-conjugated goat anti-monkey IgG or IgA (Nordic, San antibody sample to SIV envelope. The larger the conformation ratio, the greater the requirement for native envelope glycoprotein Juan Capistrano, CA), washed, incubated with o-phenylenediamine (Sigma) substrate, and read spectrophotometrically. The SIV-spestructure for antibody binding.
The antibody avidity index values of serum antibodies to the cific IgM ELISA was performed on plates coated with a 21-amino-acid synthetic peptide derived from the SIV mac transmemnative viral envelope were determined by measuring the resistance of serum antibody-envelope glycoprotein immune complexes in brane glycoprotein [23] . Each plasma sample and the positive control plasma (from an SIV-infected animal) were assayed in the ConA ELISA to 8 M urea as previously described [34] . For these avidity assays, ConA-anchored native glycoprotein was incuduplicate, and mean values of OD were calculated. Plasma samples were considered positive if the mean OD value was ú0.150 (IgG) bated with heat-inactivated SIV serum diluted to produce an OD and exceeded two times the mean OD of plasma obtained before
Immunohistochemistry staining. A standard avidin-biotin peroxidase technique was used to detect IgG in sections of formalininoculation. Saliva titers were multiplied by 2 because the sample collection and processing procedures result in a 2-fold dilution of fixed, paraffin-embedded kidney from the 3 animals in the SIV-HIS therapy group (group F, table 1). Briefly, the sections were the whole saliva. Immunoblots were performed to detect specific SIV proteins, as described previously [41] .
deparaffinized, rehydrated, and incubated with proteinase K (0.012 mg/mL; Sigma) for 15 min. The slides were blocked with horse Necropsy collection and preparation of tissue samples. The criteria for euthanasia have been described [2] . A complete necserum, washed, and incubated with IgG specific antisera for 16 h at 4ЊC (rabbit anti-human IgG; Dako, Carpenteria, CA). Binding ropsy examination was performed on all animals that died during the course of the study. Tissues collected at necropsy were fixed of the antisera was detected with anti-rabbit IgG-specific antisera (biotinylated-horse anti-rabbit IgG, Vector Laboratories). Endogin 10% buffered formalin, embedded in paraffin, cut into 6-mm sections, stained with hematoxylin-eosin, and examined by light enous peroxidase activity was quenched, and the slides were incubated with an avidin-biotin horseradish peroxidase complex (ABC microscopy. 50 ) of uncloned SIVmac251, grown in rhesus peripheral blood mononuclear cells, given orally to newborn rhesus macaques within 72 h after birth.
‡ Half-life weeks of anti -SIV IgG in plasma ({ SE) determined by antibody ELISA. § During 1st 10 weeks (g/day) was determined for each animal by regression analysis. Average growth rate of 50 uninfected controls was 6.2 g/day (95% CI, 6.1 -6.3).
x P Å .015 for immunized animals (groups D and E) vs. controls (groups A and B) by 1-sided Fisher's exact test.
Elite; Vector Laboratories) according to the manufacturer's in- pooling sera collected from macaques that had previously been vaccinated against SIV and were healthy slow progressors following challenge with pathogenic SIV mac 251; normal control serum was prepared by pooling sera from healthy SIV-seronegDecay kinetics and safety of SIV-HIS in rhesus neonates. Pooled heat-inactivated SIV-HIS was administered subcutaneative donor rhesus macaques. The characteristics of these two rhesus serum pools are presented in table 2. The SIV-HIS had ously (20 mL/kg body weight; Ç490 mg total IgG [determined by rhesus IgG radial immunodiffusion assay] per kilogram of high ELISA anti -SIV IgG titer (1:409,600), low anti -SIV IgA titer (1:400), and strong reactivity to all viral structural proteins body weight) to 2 newborn macaques (animals 29760 and 29762; table 1, group C) at 0, 7, and 14 days of age. The SIV-(including envelope glycoprotein) by immunoblotting. The SIV-HIS demonstrated envelope-specific antibody reactivity HIS was rapidly absorbed, and a high level was detected in plasma samples of each neonate by 2 days after the first adminthat was high titer, conformationally dependent, and of high avidity (table 2) . This SIV-HIS preparation contained a high istration ( figure 1A) . No toxicity or adverse effects (such as serum sickness) were observed following subcutaneous admintiter of neutralizing antibodies against laboratory-passaged SIV mac 251 and SIV Delta B670 but had a very low neutralization istration of the three doses of SIV-HIS. In addition, no infectious virus was recovered from any samples of plasma or titer against primary SIV mac 251 and undetectable neutralization against our own rhesus PBMC -grown SIV mac 251 (here desig-PBMC from these 2 infants. Following administration of the third dose of serum at 2 weeks, the plasma half-life of SIVnated as SIV mac 251-UCD), which is derived directly from the SIV mac 251 challenge stock of the present passive immunization specific IgG in these infants was estimated by linear regression to be Ç2.5 weeks (table 1) . SIV-specific IgG was detected in study (table 3). The levels of total protein and total IgG in SIV-HIS and in normal rhesus serum were similar (table 2) . plasma until Ç6 months of age with moderate titers (1:400 -1:1600) maintained for 12 weeks ( figure 1A ). Because of a Both serum pools had very high levels of RANTES chemokine (ú5000 pg/mL), presumably due to massive platelet activation low level of SIV-specific IgA in the SIV hyperimmune sera (1:400), SIV-specific IgA titers in newborn macaques following during the serum collection. No infectious virus was detected by cocultivation of the heat-inactivated SIV-HIS with passive immunization remained £1:100 during the observation period (data not shown). CEMx174 cells. figure 2A ). All 4 infected animals had an anti -SIV IgM response within 4 weeks after virus viremia, and a slower disease course (simian AIDS at 18 months). One control newborn (28981) did not become ininoculation (data not shown), but 3 infants (animals 28689, 28690, and 28948) made no SIV-specific IgG response by fected.
Passive immunization of neonates prior to oral inoculation ELISA (figure 2C) or immunoblotting (data not shown). These 3 infants had persistently high plasma viremia (figure 2B) and
with SIV mac 251. Six newborns were given SIV-HIS (20 mL/ kg body weight) subcutaneously on the day of birth (day 0); died at 11 -13 weeks of age, with clinical signs and gross and 4 were given additional doses of SIV-HIS at 7 and 14 days of of uncloned SIV mac 251, all 8 became infected and showed persistent viremia; 2 developed fatal AIDS within 8 months of age (table 1, groups D -E). Two days after administration of SIV-HIS, all 6 animals were seropositive by ELISA (figure 1B, infection (data not shown).
SIV-specific antibodies in saliva of rhesus neonates after C) and had antibodies to all viral structural proteins detected by immunoblotting (data not shown). At 2 days of age, all 6
administration with SIV-HIS. Although only a limited number of saliva samples was collected during this study, SIVanimals were inoculated orally with 1 mL (10 5 TCID 50 ) of uncloned SIV mac 251. None of these 6 infant macaques given specific IgG was detected in saliva sampled from neonates after subcutaneous administration of SIV-HIS. Titers measured by SIV-HIS prior to oral SIV inoculation became infected. No virus was recovered from any samples of plasma or PBMC SIV-specific IgG ELISA ranged from 1:8 to 1:32. In some animals, SIV-specific IgG was detected in saliva as late as 10 during the 8-to 9-month observation period. No proviral DNA could be detected by PCR in PBMC or in lymph node mononuweeks after administration of SIV-HIS (table 5) .
Passive immunization of neonates 3 weeks after oral inoculaclear cells obtained at 8 -9 months of age (data not shown). SIV antibody titers in the 6 animals declined, with a half-life tion with SIV mac 251. To study the potential therapeutic effects of SIV-HIS for infant macaques with established SIV infection, of 2 -3 weeks (similar to those in the 2 infants that had only received SIV-HIS [table 1, group C]) and were undetectable 3 newborn macaques were infected orally with uncloned SIV mac 251 and then given a single dose of SIV-HIS (20 mL/ by ELISA (figure 1B, C) and immunoblotting (data not shown) by 6 months after oral SIV inoculation. None of these 6 animals kg body weight, administered subcutaneously) 3 weeks later.
As in the SIV mac 251-infected untreated control infants, SIVhad clinical signs of immunodeficiency or serum sickness during the observation period and all were healthy at 8 -9 months specific IgM was detected in the plasma of all 3 postexposureimmunized neonates within 2 weeks following infection (data of age. When these 6 animals and the 2 that had received only the hyperimmune serum (table 1, groups C, D, and E) were not shown). One animal (29119) had a weak (1:100) SIVspecific IgG response at 3 weeks, while the other 2 had no rechallenged orally at 8 -9 months of age (i.e., when passively acquired antibodies were undetectable) with 1 mL (10 5 TCID 50 ) detectable SIV-specific IgG 3 weeks after virus inoculation. , which received normal serum 2 days prior to virus inoculation and another dose of normal serum at 1 and 2 weeks of age, is represented by ᭺. Three animals (solid lines) received SIV-HIS at 3 weeks of age (solid arrow). Levels of peripheral blood mononuclear cell (PBMC) -associated virus (A) and virus in plasma (B) were determined by limiting dilution culture assay of PBMC and plasma, respectively. Anti -SIV IgG titers (C) were determined by ELISA and are expressed as highest of 4-fold dilutions (starting from 1/100 dilution) with 2 replicates per dilution that gave positive optical density above cutoff value. CD4:CD8 T lymphocyte ratio (D) was determined by flow cytometry. NOTE. Animals 28689 and 28690 were untreated controls; animal 28948 received 3 doses of normal serum (20 mL/kg body weight, at birth and 1 and 2 weeks of age); animals 29119, 29122, and 29126 received 1 dose of SIV hyperimmune serum at 3 weeks of age. Normal total protein levels for rhesus macaques: 6.9 g/dL (range, 5.9 -7.9); normal albumin levels, 3.6 (range, 3.2 -4.1).
Following SIV-HIS administration at 3 weeks after oral SIV naive controls (figure 2). In addition, all 3 developed clinical signs consistent with serum sickness documented at 4 weeks inoculation, anti -SIV IgG levels of 1:6400 were detected at 4 weeks of age; after 4 weeks, plasma IgG levels decreased of age (i.e., 1 week after SIV-HIS administration) and persisting until the animal's demise. Clinical signs included varyrapidly, with a half-life of 1 -2 weeks (table 1), and de novo anti -SIV IgG synthesis was not detected in these 3 animals.
ing degrees of abdominal distention and peripheral edema with palpebral, facial, and scrotal edema. Deterioration of clinical Each of these 3 neonates maintained persistently high PBMCassociated and plasma viremia at levels similar to those of condition was associated with severe hypoproteinemia (2.1 - Table 5 . Anti -SIV IgG in saliva of infant macaques following administration of SIV hyperimmune serum (SIV-HIS). NOTE. SIV-HIS was given subcutaneously at 20 mL/kg body weight; SIV-specific IgG levels were determined by ELISA, and are given as reciprocal of highest dilution above assay cutoff. NA, not available.
5.4 gm/dL) and hypoalbuminemia (0.9 -2.6 gm/dL). A tranate to severe glomerulonephritis characterized by swollen hypercellular glomeruli with prominent, thickened basement sient normocytic normochromic anemia was also evident. Although no urinalysis data were available, blood loss premembranes or shrunken glomeruli with indistinct cell borders and adhesions between the glomerular tuft and Bowman's capsumptively resulted from hematuria, a common feature in glomerulonephritis. Two of the 3 animals (29119 and 29126) had sule. Numerous tubules were dilated with a glassy, eosinophilic material that contained variable numbers of neutrophils (figure poor weight gain (õ5 g/day; table 1). All 3 infants developed clinical symptoms indicative of simian AIDS, which failed to 3). In addition, there was edema, fibrosis, and a moderate lymphocytic infiltrate in the subcapsular and interstitial connecrespond to standard supportive fluid and antibiotic treatment, and were euthanatized by 11 -13 weeks of age. Their clinical tive tissue of the kidney. Animal 29122 had moderate numbers of shrunken glomeruli with indistinct cell borders and adhesigns, plus gross and microscopic pathologic changes, were consistent with terminal SIV infection (table 4) . Of interest, sions between the glomerular tuft and Bowman's capsule. In addition, there was periglomerular fibrosis and edema, fibrosis, all 3 animals had widespread Cryptosporidium infection of the epithelia of the digestive and respiratory tracts; respiratory and a moderate lymphocytic infiltrate in the interstitial connective tissue of the kidney. These histologic changes are indicaCryptosporidium infection is a rare finding in HIV-infected humans and SIV-infected macaques, including newborn mative of chronic kidney disease and are consistent with a prior episode of immune complex glomerulonephritis. By immunocaques ([42] , unpublished data).
Histologic evidence of immune-complex disease. Of the 3 histochemical analysis, IgG was detected in glomeruli in all 3 animals in this group. However, the IgG-positive glomeruli animals given SIV-HIS 3 weeks after SIV infection (table 1, group F), 2 had histologic lesions that were consistent with were rare or occasional ( figure 3 ) and, on the basis of the number of IgG-positive glomeruli seen, the amount of tissue immune-complex glomerulonephritis, while no significant lesions were found in the 3rd animal. Animal 29119 had a moderdamage in the kidneys of 29122 and 29119 was greater than expected. This discrepancy is likely related to the time interval Protection against SIV infection by passive immunization may be more easily achievable following oral than intravenous (8 -10 weeks) between the administration of the hyperimmune serum and the necropsies. Presumably much of the immune virus challenge. It is well established that mucosal surfaces are barriers to SIV [27] . Mucosal infection may result in slow virus complex deposition and glomerular damage occurred soon after the SIV-HIS was administered, and most of the immune comspread to submucosal tissues and delayed systemic dissemination; this delay may allow more time for immune effector plexes had been eliminated by the time the animals were necropsied.
mechanisms to operate than would be possible following intravenous virus inoculation. Following parenteral administration of SIV-HIS to newborn macaques, anti -SIV IgG transuded Discussion from the circulation into oral secretions; it is possible that this anti -SIV IgG reduced the dose of the challenge virus at the The goal of our experiments was to determine if passive immunization of newborn macaques with SIV-HIS can modumucosal surface or interfered with the passage of SIV to submucosal tissues. Further investigation is required to identify late infection or disease progression following oral SIV inoculation. Our study demonstrated that multiple subcutaneous adwhich stage of the initial infection the anti -SIV IgG was effective in blocking. In addition, the identity and location of the ministrations of SIV-HIS at a dosage regimen of 490 mg total IgG (determined by rhesus IgG radial immunodiffusion) per initial cellular targets of SIV and HIV during oral infection are yet to be determined but may provide important clues regarding kilogram of body weight (in the same range as the 200 mg of HIVIG per kg body weight used in ACTG 185) had no detectthe exact mechanism of antibody protection against oral infection. Of importance, our passive immunization study indicates able side effects for newborn macaques. Following subcutaneous administration of SIV-HIS to uninfected newborn mathat antiviral secretory IgA was not required to protect newborn macaques against mucosal SIV infection but that anti -SIV IgG caques, anti -SIV IgG was efficiently absorbed into the blood, and plasma levels of anti -SIV IgG declined with a half-life was sufficient. The critical role that IgG can play in limiting mucosal infection has also been shown in other virus systems, of 2 -3 weeks, slightly shorter than the reported half-life of 3 -4 weeks for HIV IgG in human infants [18, 43, 44] .
such as reovirus infection of mice [50] . The SIV-HIS in this study was collected from 6 macaques Administration of SIV-HIS to 6 neonatal macaques 2 days prior to oral SIV inoculation resulted in absorption into the that had been immunized previously with live attenuated SIV mac 1A11 and that had controlled viral replication following blood and protected all 6 newborns against SIV infection. This protection was associated with the presence of anti -SIV IgG challenge with virulent SIV mac 251; pooled serum from these animals is more likely to contain antibodies to a variety of SIV in saliva. A single dose of SIV-HIS given prior to SIV exposure was sufficient to prevent oral SIV infection, so the two extra epitopes than serum from a single vaccinated or SIV-infected animal. The SIV-HIS used in this study had strong reactivity doses of SIV-HIS that were given to 4 of these 6 animals at 1 and 2 weeks of age were probably unnecessary.
to all viral structural proteins by immunoblotting, high anti -SIV envelope antibody titer, and high avidity. It was able to We have previously demonstrated that vaccination of pregnant macaques against SIV resulted in transplacental antiviral neutralize laboratory-passaged strains of SIV rather well but had undetectable neutralization activity against the rhesus IgG transfer, which protected 2 of 3 newborn macaques against oral-conjunctival SIV infection at birth [2] . The results of the PBMC -grown SIV mac 251 stock derived from the challenge stock used in this experiment. Thus, a discrepancy exists beexperiment described herein further confirm the potential of anti -SIV IgG to protect newborn macaques against SIV infectween results obtained by in vitro neutralization assays and the observation of in vivo protection against oral infection with tion following mucosal exposure. Previous studies investigating the potential of hyperimmune serum or purified immunothis virus. A simple explanation is that in vitro neutralization assays may not predict the efficacy of specific sera in preglobulin to protect macaques against intravenous challenge with SIV have shown conflicting results [45 -48] . In addition, venting infection in vivo; this is also true in other retrovirus systems and other viral infections [51 -58] . The observation newborn macaques with maternally acquired anti -SIV antibodies (obtained through vaccination of their mothers with that protection against mucosal SIV exposure is achievable without high in vitro neutralizing titers is encouraging for HIV attenuated SIV mac 239D3) became infected following oral exposure with SIV mac 239D3; however, the challenge inoculum convaccine development.
In the current study, SIV-HIS administration protected tained a higher dose of a different virus than we used in our study [49] . The precise reasons for the protection observed in newborn macaques against oral SIV infection. These same infants, however, gradually cleared these passively acquired the current passive immunization study are unknown; however, it is likely that the combination of an oral route of virus chalantibodies and became infected when rechallenged orally with SIV when the passively acquired anti -SIV IgG was lenge, a high-quality hyperimmune serum, and a minimal virus challenge dose is responsible for the protection in our newborn undetectable. These results, suggesting that infants may become susceptible to oral HIV infection as maternally derived macaques. antiviral antibodies decrease, are consistent with observahigh-level viremia and widespread systemic virus dissemination and already demonstrate signs of immunosuppression [2, tions of breast-feeding human populations, where the risk of HIV transmission increases by prolonged breast-feeding 22, 23] . Administration of SIV-HIS when SIV antigen levels in the circulation are high apparently resulted in rapid formation practices [59 -63] .
In the present study, when the same SIV-HIS that had high of immune complexes and deposition of immune complexes in the tissues of our SIV-infected infant macaques. We have prophylactic efficacy when given prior to SIV inoculation was given to SIV-infected newborn macaques 3 weeks after oral previously shown that antiviral drug treatment of newborn macaques starting 3 weeks after oral SIV mac 251 inoculation was SIV inoculation, no therapeutic effects were detected. The 3 SIV-infected neonatal monkeys given postexposure passive imable to drastically reduce virus levels, enhance antiviral immune responses, and delay disease progression [25] . Thus, it munization had a clinical disease course similar to that of control neonates infected orally with SIV mac 251. The half-life is likely that passive immunization in the presence of highlevel viremia requires concurrent treatment with a potent antiviof SIV-specific IgG in these SIV-infected infants was shorter than that in the uninfected infants in this study, which is likely ral drug to achieve greater safety and efficacy.
In conclusion, our current passive immunization study demdue to the formation of immune complexes that were cleared rapidly from the circulation, as indicated by presence of imonstrates that antiviral IgG protected newborn macaques against oral SIV infection; secretory IgA was not required for mune complexes in the kidneys. SIV-HIS given 3 weeks after oral SIV inoculation did not reduce viral replication, and these this protection against mucosal exposure. These results suggest that intervention strategies such as active immunization of 3 infants developed clinical symptoms indicative of simian AIDS and were euthanatized within 3 months of age.
HIV-infected pregnant women and anti -HIV IgG administration may decrease the rate of perinatal HIV transmission. Haigwood et al. [64] showed that passive immunization of older macaques with purified anti-SIV IgG at 1 day and 2 weeks after intravenous inoculation with SIV sm E660 inoculation was
